Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer
Ray Pillai(VA NY Harbor Healthcare System), Thales Papagiannakopoulos(New York University)
Cited by 57
Related Papers
MicroRNA-21 Targets a Network of Key Tumor-Suppressive Pathways in Glioblastoma Cells
|Cancer Research|2008|701
The pleiotropic functions of reactive oxygen species in cancer
|Nature Cancer|2024|171
NRF2 activation induces NADH-reductive stress, providing a metabolic vulnerability in lung cancer
|Cell Metabolism|2023|142